JL6 Stock Overview
Life Science REIT plc (the “Company”) is a closed-ended Real Estate Investment Trust (“REIT”) incorporated in England and Wales on 27 July 2021. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 3/6 |
Life Science REIT plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.31 |
52 Week High | UK£0.72 |
52 Week Low | UK£0.22 |
Beta | 0.019 |
11 Month Change | -12.50% |
3 Month Change | 22.22% |
1 Year Change | -56.92% |
33 Year Change | -72.45% |
5 Year Change | n/a |
Change since IPO | -70.33% |
Recent News & Updates
Recent updates
Shareholder Returns
JL6 | DE Health Care REITs | DE Market | |
---|---|---|---|
7D | -4.9% | 0% | 0% |
1Y | -56.9% | 0% | 0% |
Return vs Industry: JL6 underperformed the German Health Care REITs industry which returned -8% over the past year.
Return vs Market: JL6 underperformed the German Market which returned 8.6% over the past year.
Price Volatility
JL6 volatility | |
---|---|
JL6 Average Weekly Movement | 13.6% |
Health Care REITs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in DE Market | 0% |
10% least volatile stocks in DE Market | 0% |
Stable Share Price: JL6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: JL6's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | n/a | Simon Farnsworth | www.lifesciencereit.co.uk |
Life Science REIT plc (the “Company”) is a closed-ended Real Estate Investment Trust (“REIT”) incorporated in England and Wales on 27 July 2021. The Company began trading on 19 November 2021 and its shares are admitted to trading on the Premium Listing Segment of the Main Market of the London Stock Exchange. The registered office of the Company is located at 6th Floor, 65 Gresham Street, London, EC2V 7NQ.
Life Science REIT plc Fundamentals Summary
JL6 fundamental statistics | |
---|---|
Market cap | €161.29m |
Earnings (TTM) | -€48.05m |
Revenue (TTM) | €24.15m |
6.7x
P/S Ratio-3.4x
P/E RatioIs JL6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JL6 income statement (TTM) | |
---|---|
Revenue | UK£20.12m |
Cost of Revenue | UK£5.61m |
Gross Profit | UK£14.51m |
Other Expenses | UK£54.55m |
Earnings | -UK£40.04m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.11 |
Gross Margin | 72.13% |
Net Profit Margin | -198.99% |
Debt/Equity Ratio | 44.2% |
How did JL6 perform over the long term?
See historical performance and comparison